PTPN2 is also expressed ubiquitously and plays multiple roles in different cells (Mosinger et al., 1992; Spalinger et al., 2018) so that the use of small inhibitors targeting PTPN2 in cancer might present the risk of causing additional side-effects. The gene discussed is PTPN2; the disease is cancer.